Trials / Completed
CompletedNCT00139555
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in patients with high risk hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | amlodipine/benazepril |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2005-08-31
- Last updated
- 2017-02-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00139555. Inclusion in this directory is not an endorsement.